Viatris (VTRS) Receivables - Other (2019 - 2026)
Viatris (VTRS) posted Receivables - Other of $545.1 million for Q2 2026, up 9.24% on a QoQ basis from $499.0 million in Q1 2026, and up 17.5% year-over-year from $463.9 million in Q2 2025.
Analysis
Viatris (VTRS) Receivables - Other (2019 - 2026) Analysis & Trends
Viatris has reported Receivables - Other for 8 years, with the latest figure at $545.1 million in Q2 2026.
- On a quarterly basis, Receivables - Other rose 17.5% year-over-year to $545.1 million in Q2 2026; TTM through Jun 2026 was $545.1 million, a 17.5% increase from a year earlier, with the FY2025 full-year figure at $453.7 million, down 16.9% from the prior year.
- Receivables - Other was $545.1 million for Q2 2026 at Viatris, up from $499.0 million in the prior quarter.
- The five-year high for Receivables - Other was $882.5 million in Q2 2024, with the low at $453.7 million in Q4 2025.
- Average Receivables - Other over 5 years is $589.0 million, with a median of $538.9 million recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other jumped 82.49% in 2024, then sank 47.43% in 2025.
- Over 5 years, Receivables - Other stood at $570.7 million in 2022, then jumped by 53.6% to $876.6 million in 2023, then slumped by 37.71% to $546.0 million in 2024, then declined by 16.9% to $453.7 million in 2025, then gained by 20.15% to $545.1 million in 2026.
- The last three Receivables - Other figures came in at $545.1 million (Q2 2026), $499.0 million (Q1 2026), and $453.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 545.10 Mn |
| Mar 31, 2026 | 499.00 Mn |
| Dec 31, 2025 | 453.70 Mn |
| Sep 30, 2025 | 459.50 Mn |
| Jun 30, 2025 | 463.90 Mn |
| Mar 31, 2025 | 540.80 Mn |
| Dec 31, 2024 | 546.00 Mn |
| Sep 30, 2024 | 861.00 Mn |
| Jun 30, 2024 | 882.50 Mn |
| Mar 31, 2024 | 842.00 Mn |
| Dec 31, 2023 | 876.60 Mn |
| Sep 30, 2023 | 507.50 Mn |
| Jun 30, 2023 | 483.60 Mn |
| Mar 31, 2023 | 475.60 Mn |
| Dec 31, 2022 | 570.70 Mn |
| Sep 30, 2022 | 504.10 Mn |
| Jun 30, 2022 | 553.30 Mn |
| Mar 31, 2022 | 537.00 Mn |
| Dec 31, 2021 | 492.00 Mn |
| Sep 30, 2021 | 504.00 Mn |